Small Cap Breakfast
Total number of AIM Companies (Incl Susp):
Total number of AIM Companies trading:
*as at close of business 20 March 2018
Standard List** of Main Market:
Total number of Standard List Companies
Total number of Standard List Companies trading:
*as at close of business 20March 2018
NEX Growth Market:
Total number of NEX Growth Market Companies (Incl Susp):
Total number of NEX Growth Market Companies trading:
*as at close of business 20March 2018
*A corporate client of Hybridan LLP
Dish of the day
No Joiners Today
Off the menu
MayAir has left AIM after being acquired by Poly Glorious
What’s cooking in the IPO kitchen?
Sativa Investments Due 29 Mar. Raising £1m at 1p. Mkt cap £4m. Investment Vehicle for investment opportunities and acquisitions in companies which are well-placed to take advantage of the dynamic regulatory environment surrounding legal Medicinal Cannabis.
Kore Potash— advanced stage mineral exploration and development company whose primary asset is its interest in the Sintoukola Project, a potash project located in the Republic of Congo. ) Measured, Indicated and Inferred Mineral Resource of 5,953Mt at an average grade of 22.0% KCl. Offer TBA. Due end March.
Perfomatrix PLC, a global end to end Performance Marketing technology and services company headquartered in the UK, is looking to join AIM in early April 2018, offer TBC
Crusader Resources, an ASX-listed public company incorporated in Australia, which is primarily focused on the exploration and development of gold assets in Brazil. Offer TBC, expected late March.
SimplyBiz, a Financial Services Firm, looking to join AIM raising £30m via placing and £34.6m via a sale of existing ordinary shares at 170p giving a market cap of £130m. Expected 4 April
Bacanora Lithium—Readmission. No new money. Mkt cap £140m. Due 21 March. the new holding company for Bacanora Minerals Ltd
Core Industrial REIT—established to invest in Irish-based industrial properties, predominantly located in the Greater Dublin Area. Vendor placing and new funds to a total of €225m, Target gross proceeds €207m. Expected Mid March
Polarean - Medical drug-device combination company operating in the high resolution medical imaging market. Offer TBC. Due 26 March
Main Market Premium Listing
Gore Street Energy Storage Fund—Seeking to raise £100m for the purposes of investment in a diversified portfolio of utility scale energy storage projects. Due 12 April.
Broker and investment platform operator AJ Bell reported to be considering London float with a valuation at £50m.
Integrated Diagnostic Holdings (LON:IDHC) $4.325 $655m
FYDec17 results from the consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria. Revenues increased 29% to EGP 1,514m in 2017 from EGP 1,171m in 2016, driven by a combination of better pricing, favourable currency translation and higher volumes. Net profit grew 44% year-on-year to EGP 384m in 2017 versus EGP 267m in 2016, benefiting from increased interest income and a lower foreign exchange loss. Recommended final dividend of $0.16 per share, equivalent to $24m in total, compared with $0.14 per share, equivalent to US$ 21 million in total in 2016.
“We enter 2018 in a strong financial position and well positioned as a leading consumer healthcare company in the Middle East and Africa. In the coming year, we will continue to focus on expanding our geographies as well as on the process of integrating our new Nigerian operations”. FYDec18E EGP 1.8bn, PBT EGP 708m.
Action Hotels (LON:AHCG) 19.25p £28.4m
The “owner, developer and asset manager of branded three and four-star hotels in the Middle East and Australia, announced the opening of Novotel Melbourne South Wharf hotel, ahead of schedule
The 347-room flagship hotel owned by Action Hotels is built on a long-term, 92-year lease plot of land held by Action Hotels and operated under AccorHotels' 4-star Novotel brand. Situated in Melbourne's newly re-developed Conference & Exhibition Centre, it is perfectly located to service both business and leisure travellers with quality affordable accommodation. The Melbourne Convention and Exhibition Centre is the largest convention centre in the southern hemisphere and currently accommodates over 5,500 delegates, hosting over 1,030 events and attracting more than 680,000 attendees, with 220 events already confirmed for the new expansion space, commencing mid-2018.”
The hotel is already proving to be in high demand with better than expected advance bookings of over AUS$3.5m.
FYDec18E rev $52.65m and $11m pre-tax loss.
The “UK developer and constructor of multi occupancy property assets, with a focus on the student accommodation and build to rent sectors, confirms that the Group has achieved planning consent on Whitefriars Lane in Coventry for 778 student beds which will be delivered ahead of the start of the 2020/21 academic year.
In addition, the Group has secured, subject to satisfactory planning, a further site in Sheffield which is targeted to deliver in excess of 700 student beds ahead of the start of the 2021/22 academic year. The growing momentum within the Group's student accommodation development business has led to the student accommodation development pipeline exceeding 9,800 beds with over 8,300 beds having received planning consent.
All the developments due for delivery ahead of the 2018/19 academic year have been forward sold. Five of the seven schemes scheduled to be delivered ahead of the 2019/20 academic year have been forward sold, with the remainder now having received planning consent.”
FYSep18E rev £342.17m and £47.43m PBT.
MedaPhor, the intelligent ultrasound software and simulation company, announced its preliminary results for the year ended 31 Dec 2017, a pivotal year where the Company expanded into the larger clinical ultrasound software market.
Revenues increased 27% to £4.2m (2016: £3.3m). North America sales double to £1.7m
Rest of World sales up 44% to £1.8m, with 83% growth for sales into China
Raised £5.4m net of costs by way of placing of shares
Year-end cash at £4.3m (2016: £1.8m)
Acquired Intelligent Ultrasound Limited bringing artificial intelligence expertise to the Group
Won UK Government grant of £0.5m for NeedleGuide development
Post year-end events
First pilot of artificial intelligence-based software in UK hospital
Commenced NeedleGuide development
Launched Bodyworks Eve, our third simulator platform, aimed at the Emergency Medicine market
Microsaic Systems (LON:MSYS) 2.1p £3.8m
The “developer of point of need mass spectrometry instruments, announced a commercial contract with UK based technology and innovation centre, the Centre for Process Innovation (CPI).
The project will focus on examining the potential of the Microsaic Mass Spectrometry (MS) offering as an online, deployable tool for the elucidation of biopharmaceutical or biologic structure during the manufacturing or bioprocessing workflow.
Microsaic's technology is a powerful point of use analysis tool which can be integrated into complex manufacturing workflows, which has the potential to be utilised in upstream cell media, or downstream biologic purification. A typical workflow could benefit from real-time data to drive production optimisation, ensure process control compliance, and reduce risk for the final product.”
SDX Energy (LON:SDX) 49.5p £101.22m
The “North Africa focused oil and gas company, is pleased to announce that the SAH-2 well on the Sebou permit (SDX 75% working interest) in Morocco has been completed and tested at a restricted rate on a 40/64" choke. The well achieved an average flow rate of conventional natural gas of 12.9 million standard cubic feet per day, with a maximum flow rate during this test of 13.5 MMscf/ d. The well will now be shut in for several days for a pressure build-up after which it will be connected to the local infrastructure and placed on test production.
In addition, the LNB-1 well on the Lalla Mimouna permit (SDX 75% working interest) in Morocco has been spud. LNB-1 is the eighth well in the Company's nine well campaign in Morocco, and the first of two remaining exploration commitment wells to be drilled on the permit in 2018. The well is anticipated to take between 15-20 days to drill and if successful it will be completed, flow tested and connected to existing infrastructure.”
4d pharma (LON:DDDD) 133.5p £87.4m
The “pharmaceutical company focusing on the development of live biotherapeutics, provides the following update in relation to the development of its lead oncology candidate, MRx0518. MRx0518 is a single strain bacterial Live Biotherapeutic Product (LBP), isolated and purified from a healthy human faecal sample, that has been shown to have immune-stimulatory characteristics and activity in a number of pre-clinical cancer models. Following a successful development programme at the Company's own GMP production plant, plans are at an advanced stage to open clinical studies in the UK and the US in the near future.
Data will be presented today at the Microbiome R&D and Business Collaboration Forum, Rotterdam by 4D's Chief Executive Officer, Duncan Peyton, identifying key aspects of the mode of action of MRx0518. Research carried out by 4D has identified a specific component of the bacteria, flaA, that plays a key role in the activity of MRx0518 by stimulating pathways that are known to be associated with the body's response to cancer.”
Beeks Financial Cloud Group (LON:BKS) 59.5p £29.24m
The cloud computing and connectivity provider for financial markets, announced entry into the cryptocurrency market via a collaboration with Gemini Trust Company, LLC a next-generation digital asset exchange and custodian. Gemini is a licensed digital asset exchange and custodian built for both individuals and institutions. As a New York trust company regulated by the New York State Department of Financial Services (NYSDFS), Gemini is a fiduciary and is therefore subject to the capital reserve requirements, cybersecurity requirements, and banking compliance standards set forth by the NYSDFS and the New York Banking Law (NYBL).” Via this new collaboration, Beeks can provide direct connectivity to Gemini via the Beeks Cloud, allowing Beeks' clients who are existing clients of Gemini to source and trade Bitcoin &Ethereum legitimately and securely. FYJun18E rev £6.2m, PBT £1.2m.
FYDec17 results from the e social video company. Revenue decreased by 48% to £9.1m (2016: £17.7m). £5.7m of this was due to a low margin advertising revenue product that was terminated by the Company in Q1 2017.
Fee Based Services revenues were impacted by loss of two major clients in Q4 2016.
CEO Claire Hungate appointed Q3 2017, prompting a strategic shift in the Company's focus to drive the Company towards profitability - gearing Brave Bison for growth in 2018.
EBITDA loss reduced by 51% to £1.7m £4.8m cash at the year end .
Analysis and strategy completed in order to launch a portfolio of new owned & operated channels in early Summer 2018.
The Group continues to trade in line with management expectations. We could see no forecasts.